Clinical Trials Directory

Trials / Completed

CompletedNCT00244413

Characteristics of Nondystrophic Myotonias

Nondystrophic Myotonias: Genotype-phenotype Correlation and Longitudinal Study

Status
Completed
Phase
Study type
Observational
Enrollment
94 (actual)
Sponsor
Richard Barohn, MD · Academic / Other
Sex
All
Age
6 Years
Healthy volunteers
Not accepted

Summary

Nondystrophic myotonias (NDM) are muscle disorders caused by genetic abnormalities in certain muscle cell membrane proteins. Individuals with NDM experience limited muscle relaxation, which causes pain, weakness, and impaired physical activity. The purpose of this study is to better characterize the clinical features and symptoms of NDM.

Detailed description

Nondystrophic myotonias are muscle disorders caused by abnormal muscle cell membrane proteins that affect the control of muscle fiber contraction. These disorders are extremely rare, and little is known about how to best treat the various subtypes of NDM. The purpose of this study is to characterize the clinical features and symptoms of NDM as well as to pair this data with specific NDM subtypes. In turn, this may lead to the development of improved treatments. The study will also establish clinical endpoints for use in future studies. This multi-center observational study will involve both a cross-sectional data analysis and a prospective longitudinal analysis. Participants will initially attend a one-day outpatient study visit. Various baseline measurements will be collected, including demographics, medical history, and quality of life measures. Blood samples will be taken to evaluate laboratory values and genetic factors. Participants will undergo manual muscle testing (MMT), clinical myotonia assessments, and functional movement assessments. Routine nerve conduction studies and electromyography (EMG) will also be performed in order to test for the presence of myotonia in specific muscles. Annual follow-up evaluations will occur 1 and 2 years following the first study visit.

Conditions

Timeline

Start date
2006-02-01
Primary completion
2012-09-01
Completion
2012-09-01
First posted
2005-10-26
Last updated
2013-03-06

Locations

6 sites across 3 countries: United States, Canada, United Kingdom

Source: ClinicalTrials.gov record NCT00244413. Inclusion in this directory is not an endorsement.